

especially those of lung scanning. Systematic reviews of diagnostic studies are hampered by the heterogeneity of results, even when attempts to define the most homogeneous set of studies are made, as in our study.<sup>13</sup> In studies dealing with quantitative D-dimer enzyme linked immunosorbent assay results, the negative likelihood ratio of grade B studies were homogeneous but lower than those of grade C studies. This discrepancy may be explained by differences in the study population and by the use of pulmonary angiography as the reference method in most grade C studies as opposed to follow-up in most grade B studies. Pulmonary angiography is difficult to interpret in patients selected on the basis of a previous lung scan result (grade C studies), leading to a high risk of misclassification.<sup>12</sup> These patients are also likely to have small pulmonary emboli, which may increase the rate of false negative D-dimer test results.<sup>14,15</sup>

As proposed by Kearon, we assumed that the diagnosis of pulmonary embolism was accurate when the post-test probability was above 85% and that pulmonary embolism could be safely ruled out when the risk of venous thromboembolism was below 5%.<sup>6</sup> As a general rule, the results suggest that discordance between clinical probability and the diagnostic test result requires additional studies.

Contributors: See bmj.com

Funding: None.

Competing interests: None declared.

Ethical approval: Not required.

- 1 Chunilal SD, Eikelboom JW, Attia J, Miniati M, Panju AA, Simel DL, et al. Does this patient have pulmonary embolism? *JAMA* 2003;290:2849-58.
- 2 Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism. *N Engl J Med* 2003;349:1247-56.
- 3 Agresti A, Coull BA. Order-restricted tests for stratified comparisons of binomial proportions. *Biometrics* 1996;52:1103-11.
- 4 DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. *Stat Med* 1996;15:1237-52.
- 5 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.

### What is already known on this topic

The accuracy of diagnostic tests for suspected pulmonary embolism varies largely between studies, and the appropriate clinical setting for their use is unclear

### What this study adds

When the clinical probability is moderate or high, pulmonary embolism is confirmed by a high probability lung scan and a positive result on spiral computed tomography or venous ultrasonography

When clinical probability is low, these results require confirmation by pulmonary angiography

In patients with a low or moderate clinical probability, the condition can be excluded by a negative quantitative D-dimer test result, a normal or near normal lung scan, or normal findings on spiral computed tomogram and venous ultrasonography

When clinical probability is high, these results require confirmation by pulmonary angiography

- 6 Kearon C. Diagnosis of pulmonary embolism. *CMAJ* 2003;168:183-94.
- 7 Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 1979;300:1350-8.
- 8 Nilsson T, Carlsson A, Mare K. Pulmonary angiography: a safe procedure with modern contrast media and technique. *Eur Radiol* 1998;8:86-9.
- 9 Stein PD, Athanasoulis C, Alavi A, Greenspan RH, Hales CA, Saltzman HA, et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. *Circulation* 1992;85:462-8.
- 10 Sackett DL, Haynes RB. The architecture of diagnostic research. In: Library B, ed. *The evidence base of clinical diagnosis*. London: BMJ Books;2002:19-38.
- 11 Kruip MJ, Leclercq MG, van der Heul C, Prins MH, Buller HR. Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. *Ann Intern Med* 2003;138:941-51.
- 12 Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. *JAMA* 1994;271:389-91.
- 13 Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. *BMJ* 2001;323:157-62. (Accepted 27 May 2005)

## Systematic comparison of four sources of drug information regarding adjustment of dose for renal function

Liat Vidal, Maya Shavit, Abigail Fraser, Mical Paul, Leonard Leibovici

### Abstract

**Objective** To compare advice on dosage adjustment for renal impairment provided by four commonly used secondary pharmacotherapeutic sources.

**Design** Systematic comparison of the definitions of renal impairment, recommendations for dosage adjustment, and the evidence in support of these recommendations in four information sources.

**Data sources** *British National Formulary*, *Martindale: the Complete Drug Reference*, *American Hospital Formulary System Drug Information*, and *Drug Prescribing in Renal Failure*.

**Review methods** Two reviewers independently extracted data on recommendations for dosage

adjustment for impaired renal function of 100 drugs often used in our hospital.

**Results** The four sources differed in their recommendations for adjustments of dosage and dosing interval. They vary in their definitions of renal impairment; some are qualitative and remain unclear. All sources provide only a general description; the methods on which the advice is based and references for original data are rarely presented.



A list of 100 drugs most commonly used at Rabin Medical Center and descriptions of the process and use of sources to reach recommendations are on [bmj.com](http://bmj.com)



This article was posted on [bmj.com](http://bmj.com) on 19 May 2005: <http://bmj.com/cgi/doi/10.1136/bmj.38476.471088.3A>

Letters p 292

Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah-Tiqva, Israel  
Liat Vidal  
*physician, research unit*  
Maya Shavit  
*pharmacist, research unit*  
Abigail Fraser  
*head of research unit*  
Mical Paul  
*attending physician*  
Leonard Leibovici  
*head of department*

Correspondence to: L Leibovici  
[leibovic@post.tau.ac.il](mailto:leibovic@post.tau.ac.il)

*BMJ* 2005;331:263-6

**Conclusions** The remarkable variation in definitions and recommendations, along with scarce details of the methods used to reach this advice, makes the available sources of drug information ill suited for clinical use. The methods used to retrieve information and use data should be described and made available to the reader. Advice on drug prescription, dose and dosing interval, contraindications, and adverse effects should be evidence based.

## Introduction

Many drugs and their metabolites are excreted through the kidneys. When renal function is impaired, the dosage or the dosing interval should be adjusted for some drugs. In an attempt to reduce medication errors by using computerised decision support ([www.amica-eu.org](http://www.amica-eu.org)) we compiled an explicit list of drugs that need adjustment for impaired renal function for use in our hospital and specified the needed adjustment.

We originally intended to use the *British National Formulary* as the primary source,<sup>1</sup> but for many drugs the *BNF* gave only a general warning, without explicit advice on how to adjust the dose or dosing interval. We consulted three other secondary sources of pharmacotherapy that are used in our hospital: *Martindale: the Complete Drug Reference*,<sup>2</sup> *American Hospital Formulary System (AHFS) Drug Information*,<sup>3</sup> and *Drug Prescribing in Renal Failure*.<sup>4</sup> The extent of information in the four sources varied, and discrepancies between their recommendations were soon evident. In order to decide on a source (or sources) to use, we compared the four sources.

## Methods

To perform a systematic comparison of four sources of information on drugs we identified the definitions that our four sources used for renal impairment, the drugs that are marked for dosage or interval adjustment for impaired renal function, and the evidence that the four sources quote in support of their recommendations. In cases of major discrepancies between sources we searched Medline to look for supporting data. Two reviewers (LV, MS) independently extracted data and settled disagreements by discussion with a third reviewer (MP).

We extracted data for 100 drugs that were most often prescribed in our hospital during 2003, judging by the defined daily dose (DDD) consumption (DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults; see [bmj.com](http://bmj.com)).

## Results

The definitions used by the four sources differed in several respects. Two of the sources (*Martindale* and *AHFS Drug Information*) use qualitative terms for renal function and impairment, without defining them (box). The other two sources use explicit but different definitions: the *BNF* uses a category of moderate renal impairment, glomerular filtration rate of 10–20 ml/minute, which is missing from the definition used in *Drug Prescribing in Renal Failure*. This difference is

not a minor one. The prevalence of this category in adults with chronic renal failure is about 5%.<sup>5</sup>

All sources provide only general information on their decision making process regarding adjustments for renal function. This information is not detailed enough to help users reach primary sources or reconstruct the process (see [bmj.com](http://bmj.com)).

The different sources expressed recommendations in quantitative and qualitative terms. None of the qualitative terms is defined. We grouped the terms into several categories (table 1) to compare them.

We also looked at the references quoted to support recommendations. The *BNF* cited no references, and the practice of the other three sources varied (table 2).

## Recommendations and comparisons

The *BNF* recommends some form of adjustment for impaired renal function for 51 drugs (54%), *Martindale* for 62 drugs (62%), *AHFS Drug Information* for 50 drugs (56%), and *Drug Prescribing in Renal Failure* for 36 drugs (53%). Precise recommendations (numerical adjustment or avoid) were advised for 25 drugs in the *BNF*, 34 in *Martindale*, 23 in *AHFS Drug Information*, and 35 in *Drug Prescribing in Renal Failure* (table 3).

We further examined how drugs that required no adjustment according to one source were categorised by a second source (table 4). The differences were

### Categories of renal impairment for dose or interval adjustment in the four sources

#### *British National Formulary*

Renal impairment is defined by glomerular filtration rate (numerical values) and divided into four grades:

- Greater than 50 ml/min
- Mild: 20-50 ml/min
- Moderate: 10-20 ml/min
- Severe: 0-10 ml/min

#### *Martindale: the Complete Drug Reference*

The following terms are used without definitions:

- Severe, chronic renal insufficiency
- Renal insufficiency
- Renal impairment
- Moderate-severe renal failure
- Chronic renal failure

(Glomerular filtration rate values are without predefined categories.)

#### *AHFS Drug Information 2004*

The following terms are used without definitions:

- Renal impairment
- Advanced chronic renal insufficiency
- Renal insufficiency, severe
- Substantially impaired renal function
- Renal disease

(Glomerular filtration rate values are without predefined categories.)

#### *Drug Prescribing in Renal Failure*

Renal function is defined by glomerular filtration rate (numerical values) and divided into three grades:

- Greater than 50 ml/min
- 10-50 ml/min
- Less than 10 ml/min

**Table 1** Terms used by the four sources to phrase recommendations. The terms are not defined in any of the sources

Category	British National Formulary	Martindale	AHFS Drug Information 2004	Drug Prescribing in Renal Failure
Q: Quantitative recommendations	Initial dose Maximal dose Specific dose	Initial dose Maximal dose Loading dose Specific dose	Initial dose Maximal dose Specific dose	Initial dose Maximal dose Specific dose
NQ: Non-quantitative recommendations	Start with small doses Avoid or use small dose Reduce dose Use lowest effective dose May need low/high doses	May require reduced doses Should be used with caution or in reduced doses The dosage may need to be adjusted	Reduced dosage may be considered Adjust dosage carefully	
V: Avoid	Avoid Avoid if possible Avoid routine use Avoid or reduce dose	Avoid Do not give Should not be used Considered by some contraindicated	Avoid Do not use Contraindicated	Avoid
C: Use with caution	Caution Manufacturer – caution Risk of adverse effects increased	Caution Use with care Use with considerable care Use with caution or not at all	Caution Manufacturer—caution Extreme caution Use with extreme caution if at all Monitor parameters Excessive adverse effects	Metabolites can accumulate

**Table 2** References quoted by the four sources to support recommendations for renal adjustment in 100 drugs

Category of reference	British National Formulary	Martindale	AHFS Drug Information 2004	Drug Prescribing in Renal Failure
No references	94	80	75	6
Pharmacokinetic studies	0	16	1	51
Supplied by the manufacturer	0	2	13	0
Case reports, anecdotes, narrative reviews	0	2	0	11
Systematic reviews, trials, cohort studies	0	0	0	0
Drugs not included	6	0	10	32

**Table 3** Category of renal adjustment for 100 drugs according to the four sources

Category	British National Formulary	Martindale	AHFS Drug Information 2004	Drug Prescribing in Renal Failure
Q: Quantitative recommendations	11	22	18	29
NQ: Non-quantitative recommendations	21	12	6	0
V: Avoid	14	12	6	6
C: Use with caution	5	16	21	1
N: Adjustment not needed	43	38	39	32
Drugs not included	6	0	10	32

remarkable—for example, 11 drugs (26%) out of 43 for which the *BNF* recommended no adjustment were categorised by *Martindale* as requiring it (dexamethasone, prednisone, methylprednisolone, hydrocortisone, paracetamol, amiodarone, promethazine, isosorbide mononitrate, isosorbide dinitrate, progesterone, loratadine). We also looked for information on the need to adjust dosage according to renal function by searching Medline, combining the names of the 11 drugs with the MeSH terms for kidney failure, glomerular filtration rate, pharmacokinetics, and adverse events. We attained helpful articles for only five drugs (paracetamol, amiodarone, isosorbide dinitrate, loratadine, and promethazine).

In seven instances (six drugs) a drug that required no adjustment according to one source was categorised as contraindicated in patients with impaired renal function by a second source (table 4).

## Discussion

Recommendations on dosage adjustment for renal impairment in sources that are considered reliable and are in common use were often worded in qualitative and undefined terms, ill suited for practical use. The

variation between sources was remarkable, including drugs for which no adjustment was recommended in one source while another marked them as contraindicated in renal failure. Some variation is to be expected as a matter of interpretation. However, clinicians are given nearly no evidence in support of recommendations and thus gain little insight into the sources of the contradiction. Only a general description of the process used to reach recommendations is provided, or none at all. Three out of the four secondary sources give no or little reference to primary sources.<sup>1-3</sup> A thorough (but not exhaustive) search of Medline failed to find primary sources for some drugs for which contradictory advice was offered. It is difficult to imagine that a clinician could perform a more comprehensive search, considering time constraints. Given the contradictions between sources and lack of primary references, judging how much these secondary sources of drug information can be relied on is also difficult.

## Limitations of the study

Our analysis is limited by several factors. We looked at only four secondary sources of information in common use in our hospital and health maintaining organisation (Clalit Health Services), but the chance

**Table 4** Drugs for which no adjustment was recommended: how were they classified in the other sources

Source in which no adjustment was required	British National Formulary				Martindale				AHFS Drug Information 2004				Drug Prescribing in Renal Failure			
	M	N	Q	V	M	N	Q	V	M	N	Q	V	M	N	Q	V
British National Formulary (n=43)	—	—	—	—	0	32	11	0	6	30	7	0	22	17	3	1*
Martindale (n=38)	1	32	4	1†	—	—	—	—	5	30	3	0	22	13	2	1*
AHFS Drug Information 2004 (n=39)	0	33	5	1‡	0	31	8	0	—	—	—	—	18	16	4	1*
Drug Prescribing in Renal Failure (n=32)	0	17	13	2§	0	13	17	2¶	1	16	15	0	—	—	—	—

M=missing. N=no adjustment required. Q=adjustment required (includes Q: quantitative recommendations, NQ: non-quantitative recommendations, and C: use with caution). V=contraindicated/avoid.

\*Terbutaline.

†Lercanidipine.

‡Ephedrine.

§Naproxen, warfarin.

¶Heparin, warfarin.

### What is already known on this subject

The dosage of many drugs should be adjusted when prescribed to patients with renal impairment

Data on the adjustment of the dose or dosing interval are available in several secondary pharmacotherapeutic sources

### What this study adds

Sources of drug information vary in their definitions and recommendations

The methods and primary sources used to reach these recommendations are not described

that more sources will reduce the variability between sources is small. We based our comparison on 100 drugs that are consumed most often in our hospital. We have little reason to assume that the choice was biased and included problematic drugs. We tackled only adjustments for renal impairment, but we can guess that the adjustment for liver failure, for example, is no better described or referenced.

### Conclusions

Looking for evidence on the efficiency of interventions, clinicians are taught to expect secondary sources (for example, systematic reviews in the *Cochrane Library*) to use their primary sources in a methodical manner: transparent and reproducible workflow, a thorough and explicit search for references, elimination of bias, and a short description of the primary sources. What should clinicians (and their patients) expect from a reliable secondary source of drug information? The methods used to retrieve information and data on use should be described and made available to the reader—for example, which kind of data are solicited from the manufacturer, how their reliability is judged, and how the data are translated into quantitative recommendations. Readers should be told if other sources of primary information are searched, which methods are used to search them, and again how the information is translated into recommendations. Primary data should be summarised, and the reader should have easy access to it. If possible, quantitative recommendations on dosages

and dosing intervals should be made. If not, the reason for the qualitative recommendation should be made clear. The basics of drug prescription—dosage and dosing interval, contraindications, and expected adverse effects—should be no less evidence based than the efficacy and effectiveness of a drug or intervention.

Contributors: LV, MS, and LL had the idea for the article. LV, MS, AF, and MP performed searches and data collection. LV and LL wrote the article and are guarantors.

Funding: EC 6th Framework IST grant, AMICA, contract number 507048.

Competing interests: None declared.

Ethical approval: Not required.

1 Joint Formulary Committee. *British national formulary*. 48th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004. [www.bnf.org/bnf/](http://www.bnf.org/bnf/)

2 Sweetman SC, ed. *Martindale: the complete drug reference*. London: Pharmaceutical Press, 2004.

3 In: McEvoy GK, Miller J, Snow EK, Welsh OH, Litvak K, eds. *American hospital formulary system (AHFS) drug information 2004*. Bethesda: American Society of Health-System Pharmacists, 2004.

4 Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, et al, eds. *Drug prescribing in renal failure: dosing guidelines for adults*. Philadelphia: American College of Physicians, 1999.

5 Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: third national health and nutrition examination survey. *Am J Kidney Dis* 1998;32:992–9.

(Accepted 27 April 2005)

doi 10.1136/bmj.38476.471088.3A

### Expression of concern

*Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up*

In the *BMJ* of 18 April 1992, we published a paper by Ram B Singh, Shanti S Rastogi, Rakesh Verma, B Laxmi, Reema Singh, S Ghosh, and Mohammad A Niaz (1992;304:1015–9). We now wish to express concern about the validity of this paper. This expression of concern is based on investigations the *BMJ* has carried out into the work of the paper's lead author and what has emerged about it and its reliability in the course of these investigations. An account of these investigations is published on page 281.<sup>1</sup> As a result of these investigations, we have reasonable grounds to doubt the validity of the 1992 paper.

1 White C. Suspected research fraud: difficulties of getting at the truth. *BMJ* 2005;331:281–8.